Rep. Tom Price (R-Ga.), President-elect Donald Trump’s nominee to head the Department of Health and Human Services, admitted on Wednesday that he decided to buy stock in an Australian biotech firm after receiving information from Rep. Chris Collins (R-N.Y.), a board member of that company.
Price’s admission that he personally chose to purchase stock in Innate Immunotherapeutics contradicts the Trump transition team’s defense of another questionable stock trade Price made. The transition team had previously said Price held a broker-operated account with Morgan Stanley and did not direct his stock trades.
Tweet
Comment